Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection (OPTIMA)
An Open-label, Non-controlled, Multicentre, Pilot Clinical Trial of Inhaled Molgramostim in Subjects With Antibiotic-resistant Non-tuberculosis Mycobacterial (NTM) Infection
Sponsor: Savara Inc.
This PHASE2 trial investigates Mycobacterium Infections, Nontuberculous and is currently completed. Savara Inc. leads this study, which shows 11 recorded versions since 2018 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE2
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — May 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Savara Inc.
For direct contact, visit the study record on ClinicalTrials.gov .